Generate Biomedicines Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Revenue	31.89	20.46
Revenue Growth (YoY)	55.89%	-
Gross Profit	31.89	20.46
Selling, General & Admin	42.26	42.09
Research & Development	224.7	175.31
Total Operating Expenses	266.96	217.4
Operating Income	-235.07	-196.94
Interest Income	13.66	18.12
Interest Expense	-1.14	-2.12
Other Non-Operating Income (Expense)	-0.26	-0.23
Total Non-Operating Income (Expense)	12.26	15.77
Pretax Income	-222.8	-181.17
Provision for Income Taxes	-0.16	-0.21
Net Income	-249.52	-213.78
Minority Interest in Earnings	-19.81	-7.61
Net Income Attributable to Preferred Dividends	46.37	40.01
Net Income to Common	-249.52	-213.78
Shares Outstanding (Basic)	33	32
Shares Outstanding (Diluted)	33	32
Shares Change (YoY)	2.77%	-
EPS (Basic)	-7.57	-6.66
EPS (Diluted)	-7.57	-6.66
Free Cash Flow	-204.13	-121.2
Free Cash Flow Per Share	-6.19	-3.78
Gross Margin	100.00%	100.00%
Operating Margin	-737.04%	-962.60%
Profit Margin	-699.10%	-886.57%
FCF Margin	-640.06%	-592.39%
EBITDA	-221.89	-181.59
EBITDA Margin	-695.72%	-887.58%
EBIT	-235.07	-196.94
EBIT Margin	-737.04%	-962.60%
Effective Tax Rate	0.07%	0.12%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q